Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, catridecacog (NovoThirteen®) cannot be endorsed for use within NHS Wales for long term prophylactic treatment of bleeding in patients with congenital factor XIII A-subunit deficiency. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | catridecacog (Novothirteen®) | |
| Formulation | 2500 units powder and solvent for solution for injection | |
| Reference number | 1387 | |
| Indication | Long term prophylactic treatment of bleeding in patients with congenital factor XIII A-subunit deficiency |
|
| Company | Novo Nordisk Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/09/2014 | |
| Further information This product is currently not marketed in the UK |
||